Companies /Basic Materials

Avient Corp

NYSE: AVNT Specialty Chemicals
$40.58
▼ $0.35 (−0.86%) today
Markets closed · 7:43am ET

Q2 2025 Earnings

Reported Aug 1, 2025, 6:01am ET · SEC source
$0.80
Beat +2.39%
EPS · est. $0.78
$866.5M
Beat +1.65%
Revenue · est. $852.4M
+4.7%
Beating market
AVNT vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0+3%Jul 31Aug 8report 6:01am ETearnings+2.1%−1.6%
−6%−3%0+3%Jul 31Aug 8earnings+2.1%−1.6%
AVNT −1.6%S&P 500 +2.1%
−6%−3%0+3%Jul 31Aug 8report 6:01am ETearnings+3.2%−1.6%
−6%−3%0+3%Jul 31Aug 8earnings+3.2%−1.6%
AVNT −1.6%NASDAQ +3.2%
+7.03%
Day of report
+0.62%
Next session
−2.75%
One week
+8.23%
30 days

S&P 500 over the same 30 days: +3.54%.

Did AVNT Beat Earnings? Q2 2025 Results

Avient Corporation delivered a clean beat to open its second half of 2025, reporting second-quarter adjusted EPS of $0.80 against a consensus estimate of $0.7813 — a 2.39% beat — while revenue of $866.50 million cleared the $852.44 million estimate by 1.65% and grew 2.0% year-over-year, marking the company's fifth consecutive quarter of organic revenue growth. The headline driver was a familiar one: double-digit demand from defense and healthcare end markets more than offset softness in consumer-facing segments, with CEO Ashish Khandpur crediting disciplined operational execution for the results. Adjusted EBITDA margins ticked up 30 basis points to 17.2%, reflecting ongoing cost controls and productivity gains. With strong Q2 operating cash flow of $113.00 million enabling $50.00 million in debt repayment, Avient narrowed its full-year adjusted EPS guidance to $2.77–$2.87 and adjusted EBITDA guidance to $545–$560 million, while guiding Q3 adjusted EPS to $0.70, an 8% increase over the prior-year period.

Key Takeaways
  • Fifth consecutive quarter of organic revenue growth
  • Defense and healthcare demand grew double digits in the quarter
  • Adjusted EBITDA margins expanded 30 basis points to 17.2%
  • Increased productivity and cost discipline
  • Favorable foreign exchange impact of 1% on sales and $0.01 on adjusted EPS

“On behalf of our entire Avient team, I'm pleased to report organic revenue growth for the fifth consecutive quarter driven by our focus on executing our strategy. Our customer focus and strong operational performance ultimately helped us deliver adjusted EPS slightly ahead of our guidance, in spite of the uncertain macro-economic backdrop in several of our key markets.”

Avient CEO, on the earnings call

Forward Guidance & Outlook

Avient narrowed its full-year 2025 adjusted EPS guidance to $2.77–$2.87 (from $2.70–$2.94) and adjusted EBITDA guidance to $545–$560 million. For Q3 2025, the company expects adjusted EPS of $0.70, representing 8% growth over Q3 2024. Management expects second-half demand trends similar to the first half, with continued momentum from defense and healthcare markets, disciplined cost controls, and productivity initiatives contributing to margin expansion. The company expects minimal direct tariff impact and targets $100–$200 million in total debt reduction by year-end.

AVNT YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$300.0M$600.0M$900.0M$849.7M$866.5MRevenue$257.6M$277.9MGross Profit$72.5M$96.1MOperating Income$33.6M$52.6MNet Income
$0$300.0M$600.0M$900.0MRevenueGross ProfitOperating IncomeNet Income

AVNT Revenue by Segment

Color, Additives and Inks$538.6M
Specialty Engineered Materials$329.7M

Figures from SEC filings and company reports. Not investment advice.